NASDAQ · HSCS
HeartSciences Inc.
$3.61+$0.24 (+7.12%)
HeartSciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.2% below the high.
Loading market information…
AMEX · VJET · USD
Stock price, earnings
Quote as of Oct 29, 2026, 07:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Flyte Aviation, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.89% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Flyte Aviation, Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$133.00. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Flyte Aviation, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
The company operates private aviation and cardiac electrophysiology businesses. Its aviation business provides short-haul private air travel using Cirrus Vision Jets and private-flight coordination services; its medical business develops technologies for treating cardiac arrhythmias.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:25 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 19, 2025 | -$6.81-161.92% vs estimate | $143.00K-52.33% vs estimate |
|---|
| Q1 2025 | Apr 4, 2025 | -$25.60-28.0% vs estimate | $149.00K-50.33% vs estimate |
|---|
| Q3 2024 | Nov 13, 2024 | -$38.19-112.17% vs estimate | $96.00K-4.0% vs estimate |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.61+$0.24 (+7.12%)
HeartSciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.2% below the high.
$4.63+$0.81 (+21.05%)
Galmed Pharmaceuticals Ltd.’s quoted price sits in the lower half of its reported 52-week range, 64.92% below the high.
$1.10-$0.05 (-4.35%)
WORK Medical Technology Group Ltd. Class A’s quoted price sits in the lower half of its reported 52-week range, 100.0% below the high.
$2.64+$0.07 (+2.72%)
PMGC Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.82% below the high.
$0.79-$0.08 (-9.35%)
iSpecimen Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.6% below the high.
$1.14-$0.06 (-5.0%)
NewGenIvf Group Limited’s quoted price sits in the lower half of its reported 52-week range, 99.99% below the high.
$0.39-$0.00 (-0.94%)
Bone Biologics Corporation’s quoted price sits in the lower half of its reported 52-week range, 83.75% below the high.
$1.54-$0.39 (-20.21%)
Universe Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.43% below the high.
